Beyond the Usual Treatment for Unmethylated GBM

Without a doubt, new treatments are needed for glioblastoma multiforme (GBM), particularly for patients with unmethylated tumors. Four clinical trials are exploring innovative therapies that hope to redefine the standard of care. These trials are not just about scientific discovery; they are about people — offering some hope for improved outcomes.

Ready to understand your options for GBM care? Contact Cancer Help Desk for personalized, expert insights.

Azeliragon in MGMT Unmethylated Glioblastoma

https://clinicaltrials.gov/study/NCT05986851

This study is investigating Azeliragon, a medicine taken by mouth that blocks the production of a substance made in the brain that sends signals to help brain tumors grow. Aliragon stops these signals from getting caught, so it might help stop these tumors and make it easier to treat them.

Doctors have given Azeliragon to over 2000 people with Alzheimer’s disease for as long as 18 months with good tolerance and results.

Personalized DNA Vaccine with Retifanlimab PD-1 Blockade Therapy in Patients with Newly Diagnosed, Unmethylated Glioblastoma

https://clinicaltrials.gov/study/NCT05743595

This study is investigating a custom-made vaccine to see if it can make special fighter cells work better against brain cancer when combined with immunotherapy. The first goal is to make sure this vaccine is safe. The big aim is to find the best combo of the vaccine and immunotherapy so they can check in a future study if this new cancer-fighting method really works for people with a type of brain tumor called GBM.

Study of IL-8 Receptor-modified CD70 CAR T Cell Therapy in CD70+ and MGMT-unmethylated Adult Glioblastoma

https://clinicaltrials.gov/study/NCT05353530

This study is for adults with glioblastoma who just had surgery to remove as much of the tumor as possible. Doctors use blood to make a new kind of cancer vaccine out of the person’s T cells (soldiers of the immune system). Patients will then get the usual cancer treatments with temozolimide and radiation. Two weeks after radiation is completed, patients will receive the one-time vaccine.

Peposertib and Radiation Therapy, Followed by Temozolomide for the Treatment of Patients with Newly Diagnosed MGMT Unmethylated Glioblastoma or Gliosarcoma

https://clinicaltrials.gov/study/NCT04555577

This study is investigating what happens when a new drug called Peposertib is given with radiation therapy to people with newly diagnosed glioblastoma or gliosarcoma. Peposertib may help radiation work better by stopping the cancer cells from growing. Investigators are hoping that using Peposertib and radiation together, followed by temozolimide, will improve GBM outcomes.